fashion -WSS

fashion

author：entertainment 2025-09-27 23:01:39 - browse：362

Mathai Mammen crosses his arms and looks into the camera — coverage from STAT — FogPharma CEO Mathai Mammen Boston Globe Photo Import

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few other biotechs have hit in recent years.

FogPharma, which is headquartered in Cambridge, Mass., is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells.

As CEO Mathai Mammen sees it, very few exemplary medicines shuttle off of drug companies’ pipelines, wade through clinical trials, and end up in the hands of physicians and patients in a given year. Far more often, pharma and biotech companies are pushing out drugs that are incrementally better than what came before, extending cancer patients’ survival by a few more months, halting their tumor growth for a little while longer. But FogPharma could deliver something truly unique, Mammen said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Case highlights the risks of experimental stem cell therapy

WSS

Helping hospitals and community health centers plan for resilience

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Readout LOUD podcast: Live from STAT Breakthrough Summit West

The drug industry sees a key ally in the Senate prevail

Attacks on the drug industry will lead to fewer breakthroughs

What the cancer research community can learn from the Covid response

focus

fashion

focus

Affirmative action in medical school literally saved lives

Arc Institute generative AI designs new CRISPR systems

After affirmative action ruling, medical educators look to 'holistic review'

Humana, CVS hope to turn members into patients at clinics

Medical leaders decry Supreme Court decision on affirmative action

Case highlights the risks of experimental stem cell therapy

Medical records are filled with copy

Readers respond to H5N1 and livestock movements, and more

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

entertainment

My superpower is killing ticks

OTC birth control: A brief history of over the counter pill design

Dramatically reducing cancer deaths requires the PASTEUR Act

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

entertainment

leisure time

leisure time

hotspot